Disease relevance of Loramet

• Effects of uremia and hemodialysis on lormetazepam disposition [1].
• Both drugs improved sleep, but compared with placebo or lormetazepam-takers, triazolam-takers became more anxious on self-ratings, were judged more often to have had a bad response by an observer, more often wrote down complaints of distress, and suffered weight loss [2].
• Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers [3].
• Important changes of muscle tone were noticed with lormetazepam at 10 to 30 min resulting in upper airway obstruction in some patients [4].
• Fixed drug eruption with lormetazepam (Noctamid) [5].

Psychiatry related information on Loramet

• Only after lormetazepam was performance on the morning reaction time test significantly affected [6].
• A significant decrease in the number of sleep stage transitions, arousals, and awakenings longer than 3 minutes was found only with lormetazepam [6].
• Effects of repeated dose nitrazepam and lormetazepam on psychomotor performance in the elderly [7].
• Psychometric scales indicated concomitant sedation and impaired concentration after lormetazepam alone [8].
• Dose-response studies of lormetazepam: efficacy, side effects, and rebound insomnia [9].

High impact information on Loramet

• A specific and sensitive radioimmunoassay has been developed for a new benzodiazepine, lormetazepam [10].
• Kinetics and biotransformation of lormetazepam. II. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect [10].
• Lormetazepam decreased wake time and sleep stage 3 and increased REM sleep compared to placebo [11].
• Measurements of a balance task, subject- and observer-rated symptoms showed a reversal of lormetazepam effects induced by flumazenil without any significant withdrawal symptoms [12].
• Controlled comparison of a new sublingual lormetazepam formulation and i.v. diazepam in outpatient minor oral surgery [13].

Chemical compound and disease context of Loramet

• Anterograde and retrograde amnesia after lormetazepam and flunitrazepam [14].
• This amnesia was smallest after lormetazepam and greatest after temazepam, which differed significantly from each other [15].
• In a study of hypothermia in the elderly the effects of chlormethiazole, thioridazine and lormetazepam were examined [16].

Biological context of Loramet

• Double-blind evaluation of the safety and hypnotic efficacy of lormetazepam in general practice [17].
• The bioavailability, pharmacokinetics, and effects on performance of lormetazepam (1 mg) have been compared using soft gelatin capsule and tablet formulations [18].
• Lormetazepam, due to its strong sedating property, showed a reduction in driving performance and an increase in reaction time and pulse rate as compared with placebo, and these effects were highly potentiated by alcohol [19].
• The pharmacokinetics of lormetazepam (LMA) was studied in five patients with intact and interrupted enterohepatic recirculation (EHR) after an oral dose of 0.03 mg/kg given as solution [20].
• A review was made of the literature exploring the psychopharmacology of lormetazepam [21].

Associations of Loramet with other chemical compounds

• Oral lormetazepam in premedication. A comparison with diazepam [22].
• Comparative study of lormetazepam and flurazepam in the treatment of insomnia [23].
• ECG activity in the sleep of insomniac patients under the influence of lormetazepam and zopiclone [24].
• Sleep and wake after benzodiazepine hypnotics: a 20-hour EEG comparison of lormetazepam and flunitrazepam [25].
• The daytime performance efficiency of 12 elderly subjects of average age 81.5 years (range 75-96 years) was examined in a cross-over study following lormetazepam 1 mg, nitrazepam 5 mg, and placebo capsules nightly for 7 nights [26].

Gene context of Loramet

• Evidence of a significant residual sedative effect was found on CFF and ARS ratings only after acute dosing with lormetazepam 2 mg [27].
• Lormetazepam 1 mg shows no residual sedative effect as measured by CFF and ARS, the morning following either acute or repeated doses [27].

Analytical, diagnostic and therapeutic context of Loramet

• After intravenous injection, lormetazepam levels in plasma fell in three (alpha, beta, gamma) dispositional phases, two of them (alpha, beta) mainly reflecting different distribution processes [10].
• The daytime psychomotor performance of 12 healthy subjects of mean age 81.4 years was examined in a double-blind crossover study following single and repeated nightly doses of nitrazepam 5 mg, lormetazepam 1 mg, and placebo [7].
• Determination of lormetazepam in plasma by gas chromatography and electron-capture detection [28].
• These results indicate that sublingual lormetazepam may have a role in anaesthesia as a premedicant and for conscious sedation [13].
• During the first three nights of withdrawal, the frequency of occurrence of rebound insomnia for drugs with relatively rapid rates of elimination (triazolam, midazolam, and lormetazepam) was significantly higher than that for the placebo control group [29].

References